NASDAQ:ADRO - Aduro BioTech Stock Price, Forecast & News

Aduro BioTech's stock was trading at $2.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ADRO stock has increased by 6.4% and is now trading at $2.51. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aduro BioTech.

Aduro BioTech is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Aduro BioTech.

Aduro BioTech Inc (NASDAQ:ADRO) issued its quarterly earnings results on Monday, March, 9th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.03. The biotechnology company had revenue of $3.63 million for the quarter, compared to analysts' expectations of $4.95 million. Aduro BioTech had a negative return on equity of 90.50% and a negative net margin of 477.30%. View Aduro BioTech's earnings history.

6 brokers have issued 1 year price objectives for Aduro BioTech's shares. Their forecasts range from $4.00 to $7.00. On average, they anticipate Aduro BioTech's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 119.1% from the stock's current price. View analysts' price targets for Aduro BioTech.

News articles about ADRO stock have trended very negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aduro BioTech earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAduro BioTech.

Aduro BioTech saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 3,450,000 shares, an increase of 8.5% from the February 13th total of 3,180,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 6.8% of the shares of the stock are short sold. View Aduro BioTech's Current Options Chain.

Some companies that are related to Aduro BioTech include Kiniksa Pharmaceuticals (KNSA), Odonate Therapeutics (ODT), Endo International (ENDP), Esperion Therapeutics (ESPR), Phoenix Tree (IMAB), Intra-Cellular Therapies (ITCI), CannTrust (CNTTF), Phathom Pharmaceuticals (PHAT), Rocket Pharmaceuticals (RCKT), Revance Therapeutics (RVNC), Aprea Therapeutics (APRE), Omeros (OMER), Applied Therapeutics (APLT), Stoke Therapeutics (STOK) and Cytokinetics (CYTK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro BioTech investors own include Regulus Therapeutics (RGLS), EXACT Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Amarin (AMRN), PTC Therapeutics (PTCT) and Micron Technology (MU).

(ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ADRO stock can currently be purchased for approximately $2.51.

Aduro BioTech has a market capitalization of $202.71 million and generates $17.26 million in revenue each year. The biotechnology company earns $-82,370,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe. View additional information about Aduro BioTech.

The official website for Aduro BioTech is http://www.aduro.com/.

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]